Reversing Immunosenescence: How mRNA Technology Turns the Liver into an Immune Factor Factory

Forum topic · ✨步子哥 · 2026-01-14

Summary

This in-depth Chinese tech forum article explains a Nature-published study from Feng Zhang's team that uses mRNA technology to reverse immunosenescence (immune aging). Instead of trying to regenerate the involuted thymus, the approach exploits the liver's robust protein synthesis capacity and the natural liver-targeting behavior of lipid nanoparticles (LNPs): intravenously injected LNP-mRNA encoding DLL1, FLT3L, and IL-7—three immune-nourishing factors that decline with age—is delivered to hepatocytes, which transiently secrete the factors into circulation. In 18-22-month-old mice, four weeks of this 'DFI' mRNA cocktail restored naive T cell numbers and TCR diversity to youthful levels, roughly rejuvenating the immune system by 24 weeks; antigen-specific CD8+ T cell responses doubled after vaccination, and 40% of aged mice with B16 melanoma achieved complete tumor regression, with synergy alongside immune checkpoint inhibitors. No autoimmunity was observed even in diabetes-prone NOD mice, and effects reversed after stopping treatment. The article also details the mechanisms of immunosenescence (thymic involution, T/B cell dysfunction, inflammaging, tolerance loss), contrasts DFI with traditional mRNA vaccines and recombinant protein therapy, and discusses hurdles before clinical translation in humans.

Overview

Immunosenescence—the multi-layered decline of the immune system with age—is a major reason the elderly are vulnerable to infections, cancer, and autoimmune disease. A Nature-published study from Feng Zhang's team proposes a striking workaround: rather than repairing the aged thymus, use mRNA technology to temporarily convert the liver into a factory producing key immune factors.

Key points on immunosenescence

Thymic involution: From puberty onward, the thymus is progressively replaced by fat tissue; by ~75 years old it produces almost no new T cells. Naive T cell output collapses, shrinking the T cell receptor (TCR) repertoire.
Functional decline of immune cells: Aged T cells proliferate poorly, secrete less IL-2/IFN-γ, and express exhaustion markers (PD-1, Tim-3). Aged B cells produce fewer and lower-affinity antibodies due to impaired germinal center maturation. Dendritic cells lose antigen-presentation efficiency; NK cell cytotoxicity weakens.
Inflammaging: Chronic low-grade inflammation (elevated IL-6, TNF-α, CRP) accelerates myeloid skewing of hematopoietic stem cells and T cell exhaustion.
Tolerance imbalance: Weakened thymic negative selection raises autoimmunity risk in old age.

Why the liver is the ideal 'temporary immune factory'

The liver retains high protein synthesis and secretion capacity even in old age, unlike the thymus.
LNP-mRNA injected intravenously naturally targets the liver: over 80% accumulates there via sinusoidal fenestrations and the ApoE/LDLR uptake pathway. The authors confirmed liver-specific expression using RIBOmap.
As a blood-circulation hub, factors secreted by hepatocytes rapidly reach immune organs and cells throughout the body.

The strategy: a DFI mRNA cocktail

Instead of encoding a pathogen antigen (as in vaccines), the therapy encodes three immune-regulatory factors that decline sharply with age:

DLL1 (Delta-like ligand 1): Notch ligand that directs lymphoid progenitors toward the T cell lineage.
FLT3L: growth factor expanding dendritic cells and lymphoid progenitors.
IL-7: essential survival and homeostatic cytokine for T cells.

Compared with recombinant protein injection, mRNA enables short-lived, controllable, physiologically secreted protein expression with proper post-translational modification—reducing risks of cytokine storms and chronic exposure.

Results in aged mice (18–22 months, roughly human 50–60s)

Four weeks of DFI treatment increased common lymphoid progenitors, restored thymopoiesis, and raised naive T cell numbers and TCR diversity—estimated as ~24 weeks (~6 months) of immune rejuvenation.
Post-treatment vaccine response: antigen-specific CD8+ T cells roughly doubled.
B16 melanoma model: 40% complete tumor regression in treated aged mice (all controls died); synergy with PD-L1 immune checkpoint blockade.
Safety: no severe autoimmunity (including in diabetes-prone NOD mice); vaccine-enhancing effects reversed within 4 weeks after stopping—indicating reversibility and preserved immune tolerance.

Clinical outlook and challenges

Potential applications: boosting elderly vaccine responses (flu, COVID-19), priming the immune system before checkpoint-inhibitor cancer therapy, and improving healthy lifespan (healthspan).
Caveats: all data are from mice; human validation requires non-human primate studies and Phase I–III trials; LNP delivery efficiency, dosing, long-term safety, autoimmunity monitoring, and a lengthy regulatory pathway remain major hurdles.

*Note: the original post is an extensive Chinese analysis (with a comparison table of DFI mRNA therapy vs. conventional mRNA vaccines vs. recombinant protein therapy); this article is a structured English summary of its findings.*